Anti-mesothelin antibody and application thereof
By designing a high-affinity fully human anti-mesothelin antibody and constructing second-generation CAR-T cells, the problems of low antibody affinity and cell exhaustion in existing antibodies have been solved, enhancing tumor-killing ability and reducing cell exhaustion levels, thus achieving more effective tumor treatment.
Patent Information
- Application Number
- CN202511227653.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-29
- Publication Date
- 2025-11-28
- Estimated Expiration
- 2045-08-29
AI Technical Summary
Existing anti-MSLN antibodies, such as SS1 antibodies, have low affinity and strong tetanic signals, which limit the activity of CAR-T cells. Furthermore, they are overly activated upon contact with free antigens in the peripheral circulation system, resulting in weakened tumor-killing ability.
A fully human anti-mesothelin antibody containing specific HCDR and LCDR sequences was developed, and second-generation CAR-T cells were constructed. The CD8a signal peptide was used to enhance membrane localization, the 4-1BB co-stimulatory domain was used to enhance T cell persistence, and the CD3ζ activation signal domain was used to enhance cell activity. Stable expression of CAR-T cells was achieved through a lentiviral vector.
It improves the affinity of antibodies for mesothelin, enhances the killing ability of CAR-T cells against tumor cells, reduces cell exhaustion levels, improves treatment efficacy, and the fully human antibody reduces immunogenicity, allowing for repeated dosing.
Smart Images

Figure CN121021700A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the technical field of tumor immunotherapy, and particularly relates to an anti-mesothelin antibody and application thereof. BACKGROUND
[0002] Mesothelin, full name mesothelin, for short MSLN, is highly expressed in solid tumors such as ovarian cancer, pancreatic cancer and mesothelioma, and is an ideal treatment target. The existing anti-MSLN antibody, such as SS1 antibody, has low affinity and strong tonic signal, which limits the activity of CAR-T cells. The existing anti-MSLN CAR-T cell, such as SS1 scfv, is activated too strongly after contacting with free antigens in the peripheral circulation system, and the degree of exhaustion of CAR-T after reaching the tumor site is high, which reduces the tumor killing ability. Therefore, there is an urgent need to provide a new mesothelin antibody. SUMMARY
[0003] The purpose of the application is to provide an anti-mesothelin fully human antibody to solve the problems in the prior art.
[0004] The technical scheme adopted by the application is: The application provides an anti-mesothelin antibody, which comprises HCDR1-HCDR3 and LCDR1-LCDR3. The amino acid sequence of HCDR1 is selected from any one of 1) to 12): 1) the amino acid sequence shown in SEQ ID NO. 24; 2) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 24; 3) the amino acid sequence shown in SEQ ID NO. 32; 4) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 32; 5) the amino acid sequence shown in SEQ ID NO. 40; 6) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 40; 7) the amino acid sequence shown in SEQ ID NO. 30; 8) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 30; 9) the amino acid sequence shown in SEQ ID NO. 38; 10) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 38; 11) an amino acid sequence as depicted in SEQ ID NO. 46; 12) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 46; the amino acid sequence of HCDR2 is selected from any one of 13) ~ 24): 13) an amino acid sequence as depicted in SEQ ID NO. 25; 14) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 25; 15) an amino acid sequence as depicted in SEQ ID NO. 33; 16) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 33; 17) an amino acid sequence as depicted in SEQ ID NO. 41; 18) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 41; 19) an amino acid sequence as depicted in SEQ ID NO. 31; 20) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 31; 21) an amino acid sequence as depicted in SEQ ID NO. 39; 22) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 39; 23) an amino acid sequence as depicted in SEQ ID NO. 47; 24) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 47; the amino acid sequence of HCDR3 is selected from any one of 25) ~ 30): 25) an amino acid sequence as depicted in SEQ ID NO. 26; 26) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 26; 27) an amino acid sequence as depicted in SEQ ID NO. 34; 28) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 34; 29) an amino acid sequence as depicted in SEQ ID NO. 42; 30) an amino acid sequence having at least 80% identity to the amino acid sequence as depicted in SEQ ID NO. 42; the amino acid sequence of the LCDR1 is selected from any one of 31) to 36): 31) the amino acid sequence as shown in SEQ ID NO. 27; 32) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 27; 33) the amino acid sequence as shown in SEQ ID NO. 35; 34) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 35; 35) the amino acid sequence as shown in SEQ ID NO. 43; 36) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 43; the amino acid sequence of the LCDR2 is selected from any one of 37) to 42): 37) the amino acid sequence as shown in SEQ ID NO. 28; 38) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 28; 39) the amino acid sequence as shown in SEQ ID NO. 36; 40) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 36; 41) the amino acid sequence as shown in SEQ ID NO. 44; 42) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 44; the amino acid sequence of the LCDR3 is selected from any one of 43) to 48): 43) the amino acid sequence as shown in SEQ ID NO. 29; 44) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 29; 45) the amino acid sequence as shown in SEQ ID NO. 37; 46) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 37; 47) the amino acid sequence as shown in SEQ ID NO. 45; 48) an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO. 45.
[0005] Preferably, the amino acid sequence of the heavy chain variable region of the anti-mesothelin antibody is any one of SEQ ID NO. 1, SEQ ID NO. 7, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 3, SEQ ID NO. 9, SEQ ID NO. 21, SEQ ID NO. 5, SEQ ID NO. 11, SEQ ID NO. 17 and SEQ ID NO. 18; the amino acid sequence of the light chain variable region is any one of SEQ ID NO. 2, SEQ ID NO. 8, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 4, SEQ ID NO. 10, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 6, SEQ ID NO. 12, SEQ ID NO. 19 and SEQ ID NO. 20.
[0006] Preferably, the anti-mesothelin antibody further comprises a heavy chain constant region and / or a light chain constant region.
[0007] The second aspect of the present application provides a chimeric antigen receptor comprising a nucleotide sequence encoding the heavy chain variable region and / or the light chain variable region.
[0008] The third aspect of the present application provides a method for preparing the chimeric antigen receptor, which comprises the following steps: connecting the heavy chain variable region, the light chain variable region and the second generation CAR sequence by homologous recombination to obtain the chimeric antigen receptor; the second generation CAR sequence comprises an intracellular signaling domain CD3ζ, a CD8a signal peptide, a CD8a hinge region, a CD8a transmembrane region and a 4-1BB costimulatory signal region; the amino acid sequence of the intracellular signaling domain CD3ζ is shown in SEQ ID NO. 48; the amino acid sequence of the CD8a signal peptide is shown in SEQ ID NO. 49; the amino acid sequence of the CD8a hinge region is shown in SEQ ID NO. 50; the amino acid sequence of the CD8a transmembrane region is shown in SEQ ID NO. 51; the amino acid sequence of the 4-1BB costimulatory signal region is shown in SEQ ID NO. 52.
[0009] The fourth aspect of the present application provides a recombinant expression vector comprising the chimeric antigen receptor.
[0010] The fifth aspect of the present application provides a CAR-T cell, wherein the CAR-T cell comprises the recombinant expression vector.
[0011] The fifth aspect of the present application provides application of the anti-mesothelin antibody, the chimeric antigen receptor, the recombinant expression vector and the CAR-T cell, wherein the application is for preparing a drug for treating cancer.
[0012] Preferably, the cancer comprises any one of breast cancer, pancreatic cancer, ovarian cancer and gastric cancer.
[0013] Compared with the prior art, the present application has the following beneficial effects: The present application provides an anti-mesothelin antibody, wherein the anti-mesothelin antibody comprises HCDR1-HCDR3 and LCDR1-LCDR3. The present application finds three high-affinity mouse-derived antibodies, i.e. 2B6, 2E5 and M10A6, and humanizes the three antibodies; wherein the affinities of 2B6 and M10A6 are significantly higher than that of SS1 antibody. On this basis, the second-generation CAR-T cell based on the above-mentioned antibodies is constructed, and the in-vitro killing effect is better than that of the conventional SS1 CAR-T, and the humanized CAR-T cell has a tumor cell killing capacity comparable to that of the mouse-derived CAR-T cell, and the cell exhaustion level is significantly reduced within a long time of 0-14 days after antigen stimulation. The chimeric antigen receptor T cell of the present application has a strong killing activity on mesothelin-positive tumor cells, uses a fully human antibody as scfv, has no immunogenicity, can be repeatedly administered, and enhances the therapeutic effect of the CAR-T cell. BRIEF DESCRIPTION OF DRAWINGS
[0014] Figure 1 For affinity comparison of different antibodies, A: mouse-derived 2E5; B: mouse-derived 2B5; C: mouse-derived 10A6.
[0015] Figure 2 For binding concentration gradient curve of different antibodies and mesothelin stable cell line HEK293T-mesothelin and EC50 value of antibody-cell binding, A: SS1 antibody; B: mouse-derived 2B6; C: mouse-derived M10A6; D: mouse-derived 2E5.
[0016] Figure 3 For a schematic diagram of the chimeric antigen receptor in the present application.
[0017] Figure 4 For comparison results of the lysis and killing capacity of mesothelin-CAR-T cells on target cells HCC1806.
[0018] Figure 5Figure for comparison of lysis and killing ability of mesothelin-CAR-T cells on target cell SKOV3 Figure 6 Figure for comparison of lysis and killing ability of mesothelin-CAR-T cells on target cell KATO3.
[0019] Figure 7 Figure for comparison of IFN-γ and TNF-α secretion ability of mesothelin-CAR-T cells, A: IFN-γ content in supernatant co-cultured with 293T; B: IFN-γ content in supernatant co-cultured with KATO3; C: IFN-γ content in supernatant co-cultured with HCC1806; D: IFN-γ content in supernatant co-cultured with SKOV3; E: TNF-α content in supernatant co-cultured with 293T; F: TNF-α content in supernatant co-cultured with KATO3; G: TNF-α content in supernatant co-cultured with HCC1806; H: TNF-α content in supernatant co-cultured with SKOV3.
[0020] Figure 8 Figure for comparison of exhaustion level of mesothelin-CAR-T cells.
[0021] Figure 9 Figure for comparison of therapeutic effect of different combinations of VH sequence and VL sequence of M10A6 in different tumor cells, A: HCC1806; B: SKOV3; C: KATO3; D: 293T.
[0022] Figure 10 Figure for comparison of therapeutic effect of different combinations of VH sequence and VL sequence of 2B6 and 2E5 in different tumor cells, A: HCC1806; B: SKOV3; C: KATO3; D: 293T. DETAILED DESCRIPTION
[0023] The application will be further described by the following specific examples, but the scope of the application is not limited thereto. The details and forms of the technical solutions of the application can be modified or replaced without departing from the spirit and scope of the application, and these modifications or replacements all fall within the protection scope of the application.
[0024] The inventive concept of the application is as follows: Second-generation CAR structure: CD8 hinge enhances spatial flexibility, CD8 transmembrane region stabilizes membrane positioning, 41BB costimulatory domain enhances T cell persistence, and CD3ζ activation signal domain.
[0025] The vector of the present application is constructed by cloning the CAR sequence into a lentiviral vector for stable expression by T cell transduction. The present application also provides a vector comprising the above-mentioned nucleic acid encoding a chimeric antigen receptor protein expressed on the surface of an immune effector cell. In a specific embodiment, the vector used in the present application is a lentiviral plasmid vector pwslv04. The plasmid belongs to a third-generation self-inactivating lentiviral vector system, which has three plasmids in common, namely a packaging plasmid psPAX2 encoding protein Gag / Pol, a packaging plasmid PMD2.G encoding Rev protein, and an empty vector pwslv04, which can be used for recombinant introduction of the nucleic acid sequence of interest, i.e., the nucleic acid sequence encoding the CAR. In the empty vector pwslv04, the expression of enhanced green fluorescent protein is regulated by the SFFV promoter. The recombinant expression vector pwslv04-CAR-T2A-eGFP containing the nucleic acid sequence of interest encoding the CAR is achieved by co-expression of eGFP and CAR through the ribosomal skipping sequence 2A from Thosea asigna virus. It should be understood that other expression vectors are also available. The present application also includes viruses containing the above-mentioned vectors. The viruses of the present application include packaged infectious viruses, and also viruses to be packaged containing the necessary components for packaging the viruses to be packaged into infectious viruses. Other viruses known in the art that can be used to transduce exogenous genes into immune effector cells and their corresponding plasmid vectors can also be used in the present application.
[0026] In order to enable those skilled in the art to better understand the technical solutions of the present application and to implement them, the present application will be further described below in conjunction with specific examples. In the description of the present application, if not specifically stated, the reagents used are commercially available, and the methods used are conventional techniques in the art.
[0027] The abbreviations used in the present application are shown in Table 1.
[0028] Example 1 An anti-mesothelin antibody is specified as follows: 1. The present application screens three murine antibodies, murine anti-mesothelin M10A6, murine anti-mesothelin 2E5 and murine anti-mesothelin 2B6, through mouse hybridoma screening.
[0029] The heavy chain amino acid sequence of the murine anti-mesothelin M10A6 scFv is shown as SEQ ID NO. 1, and the light chain amino acid sequence is shown as SEQ ID NO. 2. The heavy chain amino acid sequence of the murine anti-mesothelin 2E5 scFv is shown as SEQ ID NO. 3, and the light chain amino acid sequence is shown as SEQ ID NO. 4. The heavy chain amino acid sequence of the murine anti-mesothelin 2B6 scFv is shown as SEQ ID NO. 5, and the light chain amino acid sequence is shown as SEQ ID NO. 6.
[0030] 2. Humanization design.
[0031] The CDR regions of the murine anti-mesothelin M10A6, murine anti-mesothelin 2E5 and murine anti-mesothelin 2B6 antibodies were transplanted into the human IgG framework, i.e., the FR region of human IgG, and site-directed mutagenesis was used to reduce immunogenicity, thereby obtaining three anti-mesothelin human antibodies, i.e., human anti-mesothelin M10A6, human anti-mesothelin 2E5 and human anti-mesothelin 2B6. The CDR region sequences of the murine antibodies remain highly specific after humanization optimization.
[0032] The heavy chain amino acid sequence of the human anti-mesothelin H10A6 scFv is shown as SEQ ID NO. 7, and the light chain amino acid sequence is shown as SEQ ID NO. 8. The heavy chain amino acid sequence of the human anti-mesothelin H2E5 scFv is shown as SEQ ID NO. 9, and the light chain amino acid sequence is shown as SEQ ID NO. 10. The heavy chain amino acid sequence of the human anti-mesothelin 2B6 HscFv is shown as SEQ ID NO. 11, and the light chain amino acid sequence is shown as SEQ ID NO. 12.
[0033] 3. Back mutation of humanized antibodies.
[0034] The heavy chain amino acid sequence of the back-mutated humanized anti-mesothelin M10A6 scFv is set forth in SEQ ID NO. 13, and the light chain amino acid sequence is set forth in SEQ ID NO. 15. The heavy chain amino acid sequence of the back-mutated humanized anti-mesothelin 2B6 scFv is set forth in SEQ ID NO. 17, and the light chain amino acid sequence is set forth in SEQ ID NO. 19. The heavy chain amino acid sequence of the back-mutated humanized anti-mesothelin 2E5 scFv is set forth in SEQ ID NO. 21, and the light chain amino acid sequence is set forth in SEQ ID NO. 22.
[0035] 4. Further back-mutating on the basis of the back-mutation.
[0036] The heavy chain amino acid sequence of the further back-mutated humanized anti-mesothelin M10A6 scFv is set forth in SEQ ID NO. 14, and the light chain amino acid sequence is set forth in SEQ ID NO. 16. The heavy chain amino acid sequence of the further back-mutated humanized anti-mesothelin 2B6 scFv is set forth in SEQ ID NO. 18, and the light chain amino acid sequence is set forth in SEQ ID NO. 20. The light chain amino acid sequence of the further back-mutated humanized anti-mesothelin 2E5 scFv is set forth in SEQ ID NO. 23.
[0037] The amino acid sequences of the M10A6 related antibodies are set forth in Table 2; the amino acid sequences of the 2E5 related antibodies are set forth in Table 3; and the amino acid sequences of the 2B6 related antibodies are set forth in Table 4.
[0038] Table 2 Amino acid sequences of M10A6 related antibodies Table 3 Amino acid sequences of 2E5 related antibodies Table 4 Amino acid sequences of 2B6 related antibodies 5. Predicting the CDR regions of the anti-mesothelin antibody by the Kabat algorithm and the Chothia algorithm.
[0039] The amino acid sequences of the M10A6 CDR regions are set forth in Table 5; the amino acid sequences of the 2E5 CDR regions are set forth in Table 6; and the amino acid sequences of the 2B6 CDR regions are set forth in Table 7.
[0040] Table 5 Amino acid sequences of M10A6 CDR regions Table 6 Amino acid sequences of 2E5 CDR regions Table 7 Amino acid sequences of 2B6 CDR regions 6. Protein affinity verification of the anti-mesothelin antibodies described in this example.
[0041] From the literature "Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA- immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74. doi: 10.1073 / pnas.95.2.669. PMID: 9435250; PMCID: PMC18478.", it is known that the KD of the existing anti-MSLN antibody SS1 is 11 nM. Therefore, the above three murine antibodies were determined by surface plasmon resonance SPR, and the KD values of the modified anti-mesothelin M10A6 scFv and anti-mesothelin 2B6 scFv antibodies to MSLN were less than 5 nM, which were significantly better than the SS1 antibody. The results are shown in Figure 1 .
[0042] 7. Cell affinity verification of the anti-mesothelin antibodies described in this example.
[0043] With the known antibody SS1 as a control, the above three murine antibodies were incubated with a concentration gradient for flow detection, and the EC50 of the antibody binding to the cell was calculated by the MFI value of the antibody binding secondary antibody fluorescein. Through flow detection, the EC50 of the M10A6 scFv and M2B6 scFv antibodies binding to mesothelin stable 293T cells was 109.6 mg / ml and 78.04 mg / ml, respectively, which was significantly better than the SS1 antibody 158.5 ng / ml. The results are shown in Figure 2 .
[0044] Example 2 The application of an anti-mesothelin antibody is as follows: This embodiment is based on the anti-mesothelin antibody described in Example 1 to construct MSLN-targeted CAR-T cells. First, a chimeric antigen receptor was constructed, the structural diagram of which is shown in Figure 3 The amino acid sequences of the elements of the second-generation CAR sequence are shown in SEQ ID NO. 48-SEQ ID NO. 52.
[0045] (1) The amino acid sequence of the intracellular signal domain CD3 zeta is shown in SEQ ID NO. 48.
[0046] SEQ ID NO. 48: RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR.
[0047] (2) The extracellular signal peptide is CD8a signal peptide, and the amino acid sequence of CD8a signal peptide is shown in SEQ ID NO. 49.
[0048] SEQ ID NO 49: MALPVTALLLPLALLLHAARP.
[0049] (3) The hinge region is CD8a hinge region, and the amino acid sequence of CD8a hinge region is shown in SEQ ID NO. 50.
[0050] SEQ ID NO. 50: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD.
[0051] (4) The transmembrane region is CD8a transmembrane region, and the amino acid sequence of CD8a transmembrane region is shown in SEQ ID NO. 51.
[0052] SEQ ID NO. 51: IYIWAPLAGTCGVLLLSLVITLYC.
[0053] (5) The intracellular costimulatory signal domain contains a 4-1BB costimulatory signal region, and the amino acid sequence of the 4-1BB costimulatory signal region is shown in SEQ ID NO. 52.
[0054] SEQ ID NO. 52: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL.
[0055] 1. CAR-T cell construction process as follows: 1.1, vector construction.
[0056] In the empty vector pwslv04-eGFP, the SFFV promoter comes with the expression of enhanced green fluorescent protein eGFP, after inserting the scFv sequence in example 1 and the second generation CAR sequence in the empty vector, using Gibson homologous recombination connection method multi-fragment connection to form a recombinant expression vector encoding the target gene CAR, wherein the eGFP and the target gene CAR are co-expressed by T2A. In the immunotherapy of chimeric antigen receptor gene modified T lymphocytes, 2A sequence is often used to realize the co-expression of target gene and GFP or eGFP, and the expression of CAR can be indirectly detected by detecting GFP or eGFP. After the successful recombinant expression vector is determined by sequence, it can be prepared for lentivirus packaging. CAR-T2A-eGFP is transcribed into one mRNA, but finally translated into eGFP and anti-MSLN chimeric antigen receptor two peptide chains, wherein the anti-MSLN chimeric antigen receptor will be located on the cell membrane under the guidance of CD8a signal peptide.
[0057] The vectors containing each target CAR are as follows: Pwslv04-SS1-CAR-T2A-eGFP, Pwslv04-2B6-CAR-T2A-eGFP, Pwslv04-2E5-CAR-T2A-eGFP and Pwslv04-M10A6-CAR-T2A-eGFP.
[0058] 1.2, lentivirus preparation.
[0059] When the density of 293 cells is close to about 90%, passaging is carried out, and trypsin preheated at 37℃ is added for digestion. The digested and centrifuged cells are mixed and seeded in a 10cm culture dish. The cells are incubated in a 37℃ incubator containing 5% CO2 for 24h, and when the cells adhere to the wall and occupy more than 50% of the total area of the culture dish, the lentivirus plasmid is transfected.
[0060] Take a sterile 1.5ml EP tube, add 800μL serum-free DMEM, add 2.5μg pMD2G, 7.5μg psPAX2, 10μg recombinant expression vector, add PEI 24μl; vortex for 15s, stand at room temperature for 20min. Add the mixture to the cell culture dish, shake the dish gently, then place it in a 37℃ incubator with 5% CO2. After 16h, remove the culture medium, add an appropriate amount of 37℃ preheated 20% FBS complete medium, continue to incubate the cells in the incubator. 48h after transfection, collect the supernatant containing lentivirus around 72h. Centrifuge at 1500rpm for 5min to remove cell debris. The supernatant is filtered with 0.45μm filter membrane for standby, and the virus liquid is collected. The experimental cells to be transfected are plated in a 35mm culture dish, and the medium is changed after 24h. The optimal density is 50%. The first time to add the virus liquid collected after transfection for 24h. According to the situation, the virus liquid can be infected again. After the cells grow, they are subcultured or detected for expression.
[0061] 1.3, primary T cell isolation.
[0062] Adjust the density of PBMC cells to 1×10 8 cells / mL, total volume not more than 2.5mL, resuspended in a 5mL round bottom tube. Take out the magnetic beads and blow them up and down with a pipette gun for at least 5 times, mix thoroughly. Take 100μL magnetic beads / mL to the above sample, mix thoroughly, and incubate at room temperature for 30min. Add complete medium to the total volume of 2.5mL in the tube, insert the tube into the magnetic pole with the cap open, and stand at room temperature for 5min. After incubation, the tube remains in the magnetic pole, and the cells in the tube are poured out by inverting the tube gently. Repeat the washing once. Resuspend the cells in X-vivo15 medium, and add 100U / mL IL-2, 5ng / mL IL-15 and 10ng / mL IL-7.
[0063] 1.4, preparation of CAR-T cells by lentivirus infection of T cells, the specific experimental steps are as follows: According to MOI=20, calculate the required virus amount. Take the virus out of the-80℃ refrigerator, and quickly melt it in a 37℃ water bath. Add the calculated virus amount in the 24-well plate, add DEAE, IX, mix thoroughly, and use sealing film to seal the four sides of the 24-well plate, centrifuge at 800g for 1h. After centrifugation, tear off the sealing film, and place the 24-well plate in a 37℃ incubator with 5% CO2, continue to culture for 24h. Centrifuge at 250g for 10min, remove the culture medium supernatant containing virus, resuspend the cell pellet with fresh medium, and transfer the cells to a new 24-well plate for continuous culture for 6 days for standby.
[0064] 2, verification of the killing effect of CAR-T cells. The specific experimental steps are as follows:
[0065] Adjust the target cell state to logarithmic growth phase, before the experiment, need to be subcultured 2 times; trypsin to adhere to the target cells are suspended in complete medium, take a new 96-well plate, according to the amount of 100 μL / well of target cells. 96 well plate four unused holes, 100 μL of sterile water per well, to prevent the middle of the experimental hole water evaporation. The hole plate is placed in a 5% CO2 37 ℃ incubator, overnight culture.
[0066] Centrifugal collection of the above prepared CAR-T cells, using serum-free X-VIVO15 medium resuspended; from the incubator to the 96-well plate with target cells, the hole in the culture medium is completely sucked out, with sterile PBS gently wash the cells once, then according to the ratio of E / T = 1:1, the addition of CAR-T cells, and the final volume of 100 μL / well; 96 well plate is placed in a 5% CO2 37 ℃ incubator, incubated for 72 h. After incubation, the hole plate from the incubator, take a picture to detect the target cell killing. Results as shown in Figures 4-6 The targeting mesothelin chimeric antigen receptor T cells, at the ratio of 1:1, can efficiently mediate T cell killing of tumor cells. 2B6, 2E5 and M10A6 CAR-T cells were used together to verify the killing effect, and the results were similar to the single effect. Here is not shown separately.
[0067] CAR-T cells based on humanized recombinant expression vector showed that they can still efficiently mediate T cell killing of tumor cells. Results are shown in Figure 9 and Figure 10 It can be seen that the humanization of antibody sequence does not affect the killing of CAR-T cells to target cells.
[0068] Figure 9 M10A6 different VH sequence and VL sequence combination in different tumor cells. M10A6: VH and VL are murine; HG-LG: VH and VL are human; HG-L5A: VH is human, VL is a back mutation; HG-LIN: VH is human, VL is a further back mutation; H5A-LG: VH is a back mutation, VL is human; H5A-L5A: VH is a back mutation, VL is a back mutation; H5A-LIN: VH is a back mutation, VL is a further back mutation; HIN-LG: VH is a further back mutation, VL is human; HIN-L5A: VH is a further back mutation, VL is a back mutation; HIN-LIN: VH is a further back mutation, VL is a further back mutation; NC is the control group; HBEST-LBEST is the result of the best VH and VL pairing.
[0069] Figure 10Therapeutic effects of different combinations of VH and VL sequences of 2B6 and 2E5 in different tumor cells. The first 3 are the results of 2B6, and the last 3 are the results of 2E5, 2B6: both VH and VL are murine; 2E5: both VH and VL are murine; HGL5A: VH is human, and VL is a back mutation; H5ALG: VH is a back mutation, and VL is human; HINLG: VH is a further back mutation, and VL is human; HGLIN: VH is human, and VL is a further back mutation; HGLG: both VH and VL are human.
[0070] 3. CAR-T cell cytokine secretion level detection.
[0071] After the end of the culture, the well plate was taken out of the incubator, and the 96-well plate was centrifuged at 400g at room temperature for 5 min. The plate was gently taken out, and 150 μL of culture medium supernatant was transferred from each well. The expression of IFN-γ and TNF-a was detected using an ELISA kit, and the OD value was read using an enzyme-labeled instrument. The data obtained above were plotted using GraphPad 9.0. As shown in Figure 7 , after the mesothelin-targeting chimeric antigen receptor T cells bind to the target tumor cells, they can effectively activate the primary T cells and cause an increase in the expression amount of cytokine secretion.
[0072] 0. CAR-T cell exhaustion level detection.
[0073] After 3 days of T cell activation, the virus transfected with SS1, 2E5 and 2B6, on the 13th, 17th and 24th days of activation, the expression of PD1 and Tim3 of the virus-infected T cells was detected by flow cytometry analysis. As shown in Figure 8 , the exhaustion level of 2B6-CAR-T cells is the lowest, followed by 2E5-CAR-T cells, and the exhaustion level of SS1-CAR T cells is much higher than that of 2E5-CAR-T and 2B6-CAR-T since the 13th day.
[0074] The technical features of the above-described embodiments can be combined in any way. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described, but as long as the combinations of the technical features do not contradict, they should be considered within the scope of the present disclosure.
[0075] The above-described embodiments only express several embodiments of the present application, and the description is more specific and detailed, but it should not be understood as limiting the scope of the patent. It should be noted that for ordinary skilled persons in the art, without departing from the concept of the present application, a number of modifications and improvements can be made, which are within the scope of the present application.
Claims
1. An anti-mesothelin antibody, characterized in that, The anti-mesothelin antibody comprises HCDR1~HCDR3 and LCDR1~LCDR3; The amino acid sequence of HCDR1 is selected from any one of cases 1) to 12): 1) The amino acid sequence as shown in SEQ ID NO.24; 2) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 24; 3) The amino acid sequence as shown in SEQ ID NO.32; 4) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.32; 5) The amino acid sequence as shown in SEQ ID NO.40; 6) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.40; 7) The amino acid sequence as shown in SEQ ID NO.30; 8) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 30; 9) The amino acid sequence as shown in SEQ ID NO.38; 10) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 38; 11) The amino acid sequence as shown in SEQ ID NO.46; 12) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 46; The amino acid sequence of HCDR2 is selected from any one of cases 13) to 24): 13) The amino acid sequence as shown in SEQ ID NO.25; 14) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 25; 15) The amino acid sequence as shown in SEQ ID NO.33; 16) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 33; 17) The amino acid sequence as shown in SEQ ID NO.41; 18) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.41; 19) The amino acid sequence shown in SEQ ID NO.31; 20) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.31; 21) The amino acid sequence as shown in SEQ ID NO.39; 22) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.39; 23) The amino acid sequence as shown in SEQ ID NO.47; 24) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.47; The amino acid sequence of HCDR3 is selected from any one of the following: (25) to (30). 25) The amino acid sequence as shown in SEQ ID NO.26; 26) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 26; 27) The amino acid sequence as shown in SEQ ID NO.34; 28) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.34; 29) The amino acid sequence shown in SEQ ID NO.42; 30) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 42; The amino acid sequence of LCDR1 is selected from any one of cases 31) to 36): 31) The amino acid sequence as shown in SEQ ID NO.27; 32) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.27; 33) The amino acid sequence as shown in SEQ ID NO.35; 34) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 35; 35) The amino acid sequence shown in SEQ ID NO.43; 36) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 43; The amino acid sequence of LCDR2 is selected from any one of the following: (37) to (42). 37) The amino acid sequence as shown in SEQ ID NO. 28; 38) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 28; 39) The amino acid sequence shown in SEQ ID NO.36; 40) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.36; 41) The amino acid sequence as shown in SEQ ID NO.44; 42) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 44; The amino acid sequence of LCDR3 is selected from any one of cases 43) to 48): 43) The amino acid sequence as shown in SEQ ID NO. 29; 44) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO. 29; 45) The amino acid sequence as shown in SEQ ID NO.37; 46) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.37; 47) The amino acid sequence as shown in SEQ ID NO.45; 48) An amino acid sequence that has at least 80% identity with the amino acid sequence shown in SEQ ID NO.
45.
2. The anti-mesothelin antibody as described in claim 1, characterized in that, The amino acid sequence of the heavy chain variable region of the anti-mesothelin antibody is any one of the sequences shown in SEQ ID NO.1, SEQ ID NO.7, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.3, SEQ ID NO.9, SEQ ID NO.21, SEQ ID NO.5, SEQ ID NO.11, SEQ ID NO.17, and SEQ ID NO.
18. The amino acid sequence of the light chain variable region is any one of the sequences shown in SEQ ID NO.2, SEQ ID NO.8, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.4, SEQ ID NO.10, SEQ ID NO.22, SEQ ID NO.23, SEQ ID NO.6, SEQ ID NO.12, SEQ ID NO.19, and SEQ ID NO.
20.
3. The anti-mesothelin antibody as described in claim 1, characterized in that, The anti-mesothelin antibody also includes a heavy chain constant region and / or a light chain constant region.
4. A chimeric antigen receptor, characterized in that, The chimeric antigen receptor comprises a nucleotide sequence encoding the heavy chain variable region and / or the light chain variable region as described in claim 2.
5. The method for preparing the chimeric antigen receptor as described in claim 4, characterized in that, The method is as follows: The chimeric antigen receptor is obtained by linking the heavy chain variable region, the light chain variable region, and the second-generation CAR sequence through homologous recombination. The second-generation CAR sequence includes the intracellular signaling domain CD3ζ, CD8a signal peptide, CD8a hinge region, CD8a transmembrane region, and 4-1BB co-stimulatory signaling region. The amino acid sequence of the intracellular signaling domain CD3ζ is shown in SEQ ID NO.48; The amino acid sequence of the CD8a signal peptide is shown in SEQ ID NO.49; The amino acid sequence of the CD8a hinge region is shown in SEQ ID NO.50; The amino acid sequence of the transmembrane region of CD8a is shown in SEQ ID NO.51; The amino acid sequence of the 4-1BB co-stimulatory signal region is shown in SEQ ID NO.
52.
6. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the chimeric antigen receptor as described in claim 4.
7. A CAR-T cell, characterized in that, The CAR-T cells comprise the recombinant expression vector of claim 6.
8. The application of the anti-mesothelin antibody as described in claim 1, the chimeric antigen receptor as described in claim 4, the recombinant expression vector as described in claim 6, and the CAR-T cells as described in claim 7, characterized in that, The application refers to the preparation of drugs for treating cancer.
9. The application as described in claim 8, characterized in that, The cancers mentioned include any one of breast cancer, pancreatic cancer, ovarian cancer, and stomach cancer.
Citation Information
Patent Citations
Anti-mesothelin full-human antibody and immune effector cell of targeted mesothelin
CN106467573A
Chimeric antigen receptor targeting mesothelin and application thereof
CN113527515A
Anti-mesothelin nano antibody and application thereof
CN114276454A
Anti-mesothelin nano antibody with high affinity and application thereof
CN116063531A
